Revenue: As of FY2025 Q3, the actual value is USD 4.043 M.EPS: As of FY2025 Q3, the actual value is USD -5.33.EBIT: As of FY2025 Q3, the actual value is USD -7.754 M.<h3>Segment Revenue</h3><ul><li>Non-licensing Revenue: $3.511 million for the three months ended September 30, 2025, and $5.843 million for the nine months ended September 30, 2025.</li><li>Licensing Revenue: $0.532 million for the three months ended September 30, 2025, and $0.780 million for the nine months ended September 30, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $1.375 million for the three months ended September 30, 2025, and $2.147 million for the nine months ended September 30, 2025.</li><li>Operating Loss: - $8.888 million for the three months ended September 30, 2025, and - $19.387 million for the nine months ended September 30, 2025.</li><li>Net Loss: - $10.665 million for the three months ended September 30, 2025, and - $19.651 million for the nine months ended September 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $20.519 million for the nine months ended September 30, 2025.</li><li>Net Cash Used in Investing Activities: - $55.075 million for the nine months ended September 30, 2025, primarily due to acquisitions.</li><li>Net Cash Provided by Financing Activities: $79.997 million for the nine months ended September 30, 2025, mainly from proceeds from convertible notes.</li></ul><h3>Unique Metrics</h3><ul><li>Convertible Notes: $90.0 million in borrowings as of September 30, 2025, with $10.0 million recorded as current and $72.0 million as long-term related party debt.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to expand its hemp-derived THC product offerings and increase market penetration in existing and new markets. The focus is on leveraging the acquired brands and enhancing distribution channels.</li><li>Non-Core Business: The company has exited the Extraction Business and sold the Cultivation Business to focus on its core hemp-derived product lines.</li></ul>

RYTHM | 10-Q: FY2025 Q3 Revenue: USD 4.043 M